A new strategy to overcome tumour-induced immunosuppression
Researchers have found that blocking key enzymes could boost anti-cancer T cell responses and resistance to immunosuppression.
List view / Grid view
Researchers have found that blocking key enzymes could boost anti-cancer T cell responses and resistance to immunosuppression.
Scientists have demonstrated how killer T cells used in immunotherapy to eliminate cancer cells can also destroy tumour lymphatic vessels, thus greatly reducing the risk of metastasis.
Researchers have developed an immunotherapy platform to improve both antitumor immune responses and responses to checkpoint inhibitors
In their latest study, researchers at Moffitt Cancer Center have shown that cancer cells in an acidic environment undergo lipid synthesis and accumulation.
Researchers have developed a promising new tool that accurately uses genomic data to predict disease risk across diverse populations.
The new findings could help scientists to identify new targets and develop initial concepts to better restrain the metastatic spread of breast cancer.
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
A scientist at the University of Houston receives a $2 million grant to innovate computer-aided drug discovery for breast cancer.
Researchers have developed a new way to generate breast tumour models faster, more reliably and with less immune variability than existing models.
A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
CRISPR holds great promise in advancing pharmacological research and has fuelled the rapid expansion of using gene-edited cells for drug discovery processes. CRISPR-Cas9 dropout screens have emerged as a useful tool for high-throughput large-scale loss-of-function screens, which seek to identify the relationship between genotype and phenotype. Dr Pushpanathan Muthuirulan, Research…
Interleukin 13 receptor alpha 2 was found in increased rates in cancer cells that metastasised to the brain and lungs, a new study has shown.